Atossa Genetics NASDAQ: ATOS is a Seattle-based healthcare firm that specializes in breast health. The company focuses on the development and marketing of pharmaceuticals for the treatment of breast cancer. The company is named after the Persian Queen Atossa, who became the first woman in recorded history with breast cancer around 470 B.C. In 2000, Dr. Steven Quay, a physician specializing in biological chemistry, invented a preventative screening method to identify precursors to breast cancer and to treat precancerous lesions. In May 2016, Dr. Quay and Dr. Shu-Chih Chen, Ph.D. had published the book, “Nipple Aspirate Fluid Exfoliative Cytopathology and Molecular Biomarkers: Current Role in the Management of Breast Health,” which describes the status of research and clinical practice involving the Atossa technology.